Related Experiment Video
Updated: Apr 29, 2026
11:15
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
7.2K
Dendritic cell immunotherapy for glioblastoma
Stavros Polyzoidis1, Keyoumars Ashkan
1Department of Neurosurgery, King's College Hospital, Denmark Hill London, SE5 9RS, UK.
Expert Review of Anticancer Therapy
|May 23, 2014
Summary
Dendritic cell immunotherapy shows promise for glioblastoma multiform treatment, with early trials indicating good results and low toxicity. Further research is needed to address future challenges for this innovative therapy.
Area of Science:
- Immunotherapy
- Oncology
- Neuro-oncology
Background:
- Dendritic cell immunotherapy is being explored as a novel treatment for glioblastoma multiform.
- Early-phase clinical trials (Phase I and II) have shown promising outcomes.
Discussion:
- This editorial reviews the current standing of dendritic cell immunotherapy in glioblastoma treatment.
- It highlights the observed favorable outcomes and minimal toxicity in initial patient studies.
Key Insights:
- Dendritic cell immunotherapy represents a potentially valuable addition to multimodal glioblastoma therapy.
- Initial clinical data suggest a favorable safety and efficacy profile.
Outlook:
- The editorial discusses the ongoing challenges and future directions for dendritic cell immunotherapy in glioblastoma.
- Continued research is essential to overcome hurdles and optimize this therapeutic approach.
